Millennium Management’s ADC Therapeutics ADCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ADCT
ACM
OM
Millennium Management's ADCT Position: Q3 2026 in Review
Millennium Management sold out of ADC Therapeutics (ADCT) in Q3 2026, closing a stake of 2,899,535 shares — an estimated $3.1M sold.
Millennium Management first reported a position in ADCT in Q2 2020 and held it in 21 quarters. The position peaked at $13.1M in Q4 2022. 110 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.
- Millennium Management reported no remaining ADC Therapeutics position as of Q3 2026 after selling out during the quarter.
- Millennium Management sold 2,899,535 ADC Therapeutics shares in Q3 2026, an estimated $3.1M.
- Millennium Management first reported a position in ADC Therapeutics in Q2 2020 and held it in 21 quarters.
- Millennium Management's ADC Therapeutics position peaked at $13.1M in Q4 2022.
- 110 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.
Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.